Use of oral contraceptives in overweight women
- Autores: Unanyan A.L.1, Arakelov S.E.2,3, Polonskaya L.S.2,3, Guriev T.D.1, Alimov V.A.1, Baburin D.V.1, Kadyrova A.E.1, Bonetsky B.A.1, Kossovich Y.M.1
-
Afiliações:
- I.M. Sechenov First Moscow State Medical University
- PFUR
- 53rd City Clinical Hospital
- Edição: Nº 12 (2014)
- Páginas: 100-104
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247328
- ID: 247328
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
Ara Unanyan
I.M. Sechenov First Moscow State Medical University
Email: 9603526@mail.ru
Doctor of Medicine, professor of 1st Department of obstetrics and gynecology
Sergey Arakelov
PFUR; 53rd City Clinical Hospital
Email: 53mosgkb@gmail.com
MD, Chief Physician of 53rd City Clinical Hospital, assistant professor of Department of obstetrics and gynecology
Lusine Polonskaya
PFUR; 53rd City Clinical Hospital
Email: ml.7951447@gmail.com
MD, head of gynecology department of 53rd City Clinical Hospital, assistant professor of Department of obstetrics and gynecology
Taymuraz Guriev
I.M. Sechenov First Moscow State Medical University
Email: 9603526@mail.ru
Doctor of Medicine, professor of obstetrics and gynecology
Vladimir Alimov
I.M. Sechenov First Moscow State Medical University
Email: alimovvladimirr@gmail.com
clinical intern of the department of obstetrics and gynecology, pediatric faculty
Dmitry Baburin
I.M. Sechenov First Moscow State Medical University
Email: 9603526@mail.ru
assistant professor of 1st Department of obstetrics and gynecology
Aizada Kadyrova
I.M. Sechenov First Moscow State Medical University
Email: 9603526@mail.ru
post-graduate of the 1st Department of obstetrics and gynecology
Boris Bonetsky
I.M. Sechenov First Moscow State Medical University
Email: boris.bonetsky@yandex.ru
student of the medical faculty
Yulia Kossovich
I.M. Sechenov First Moscow State Medical University
Email: 9603526@mail.ru
post-graduate of the 1st Department of obstetrics and gynecology
Bibliografia
- Доклад о ситуации в области неинфекционных заболеваний в мире. ВОЗ; 2010. [Report on the situation in the field of non-communicable diseases in the world, WHO. 2010. (In Russian)]
- Прилепская В.Н., Межевитинова Е.А., Сасунова Р.А., Иванова Е.В., Летуновская А.Б., Набиева К.Р. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акушерство и гинекология. 2012; 2: 81-5. [Prilepskaya V.N., Mezhevitinova E.A., Sasunova R.A., Ivanova E.V., Letunovskaya A.B., Nabieva K.R. Results of the clinical use of a drospirenone-containing agent in women with severe premenstrual syndrome. Akusherstvo i ginekologiya/Obstetrics and Gynecology. 2012; 2: 81-5. (In Russian)]
- V Всероссийский конгресс «Амбулаторно-поликлиническая практика в эпицентре женского здоровья»: Национальные критерии приемлемости методов контрацепции. Эффективная фармакотерапия. Акушерство и гинекология. 2012; 3: 68-73. [V All-Russian Congress „Outpatient practice in the midst of the women’s health”: National eligibility criteria of contraceptive methods. Effektivnaya farmakoterapiya. Akusherstvo i ginekologiya. 2012; 3: 68-73. (In Russian)]
- Adamska E., Ostrowska L., Górska M., Krętowski A. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes. Prz. Gastroenterol. 2014;9(2):69-76. doi: 10.5114/pg.2014.42498.
- Al-Fadhli M.A., Saraya M.A., Qasem J.A. Evaluation of leptin, interleukin-1 beta and tumor necrosis factor alpha in serum of malaria patients as prognostic markers of treatment outcome. Asian Pac. J. Trop. Biomed. 2014; 4(6): 441-5.
- Caprio M., Antelmi A., Chetrite G., Muscat A., Mammi C., Marzolla V. et al. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospi renone: potential implications for the treatment of metabolic syndrome. Endocrinology. 2011; 152(1): 113-25.
- Dedov I.I., Melnichenko G.A,, Grigoryan O.R., Grodnitskaya E.E., Andreeva E.N., Shestakova M.V. Contraception in perimenopausal women with diabetes mellitus. Gynecol. Endocrinol. 2006; 22(4): 198-206.
- Finucane M.M., Stevens G.A., Cowan M.J., Danaei G., Lin J.K., Paciorek C.J. et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 337(9765): 557-67.
- Fruhbeck G., Gomes-Ambrosi J., Muruzábal F.J., Burrell M.A. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 2001; 280: E827-E847.
- Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009.
- Guang-Sheng F., Mei-Lu B., Li-Nan C., Xiao-Ming C., Zi-Rong H., Zi-Yan H. et al. Efficacy and safety of the combined oral contraceptive ethinylestradiol/ drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin. Drug Investig. 2010; 30(6): 387-96.
- Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst. Rev. 2012; (2): CD006586.
- Marzolla V., Armani A., Zennaro M.C., Cinti F., Mammi C., Fabbri A. et al. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol. Cell. Endocrinol. 2012; 350(2): 281-8.
- Naessén S., Carlström K., Byström B., Pierre Y., Hirschberg A.L. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology. 2007; 32(5): 548-54.
- Policy and action for cancer prevention. Food, nutrition, and physical activity: a global perspective. Washington, DC: World Cancer Research Fund/ American Institute for Cancer Research; 2009.
- Ribeiro L.F., Catarino T., Santos S.D., Benoist M., van Leeuwen J.F., Esteban J.A., Carvalho A.L. Ghrelin triggers the synaptic incorporation of AMPA receptors in the hippocampus. Proc. Natl. Acad. Sci. USA. 2014; 111(1): E149-58. doi: 10.1073/pnas.1313798111.
- Ronconi V., Turchi F., Appolloni G., di Tizio V., Boscaro M., Giacchetti G. Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists. Curr. Vasc. Pharmacol. 2012; 10(2): 238-46.
- Rosen E.D., Spiegelman B.M. Molecular regulation of adipogenesis. Ann. Rev. Dev. Biol. 2000; 16: 145-71.
- Sundblad C., Landén M., Eriksson T., Bergman L., Eriksson E. Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J. Clin. Psychopharmacol. 2005; 25(1): 85-8.
- World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. Geneva: WHO; 2009. Available at: http://www.who.int/reproductive-health/publications/mec/family_planning/9789241563888/en/index. html.
- Zorrilla E.P., Iwasaki S., Moss J.A., Chang J., Otsuji J., Inoue K. et al. Vaccination against weight gain. Proc. Natl. Acad. Sci. USA. 2006; 103(35):
Arquivos suplementares
